Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer

Inclusion Criteria: * Patients must be platinum resistant * No prior anthracycline use * PS ≤ 2 * Lab values within certain limits (ANC \> 1000, platelets \> 100,000; ALT, AST 2x ULN, creatinine \< 2.0); * No more than 3 prior chemotherapy regimens, only 2 of which can have included platinum-containing regimens. * Use of effective means of contraception in subjects of child-bearing potential Exclusion Criteria: * Disease-Specific Exclusions: * Evidence of complete or partial bowel obstruction * Need for IV hydration or TPN * \> 2 prior abdominal surgeries * History of gastrointestinal perforation * Gastrointestinal perforation due to any other cause within the last 6 months * General Medical Exclusions: * Inability to comply with study and/or follow-up procedures * Life expectancy of less than 12 weeks * Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored Avastin cancer study * Avastin-Specific Exclusions: * Inadequately controlled hypertension (defined as systolic blood pressure greater than 150 and/or diastolic blood pressure \> 100 mmHg on antihypertensive medications) * Any prior history of hypertensive crisis or hypertensive encephalopathy * New York Heart Association (NYHA) Grade II or greater congestive heart failure (see Appendix E of the protocol) * History of myocardial infarction or unstable angina within 6 months prior to study enrollment * History of stroke or transient ischemic attack within 6 months prior to study enrollment * Known CNS disease * Significant vascular disease (e.g., aortic aneurysm, aortic dissection) * Symptomatic peripheral vascular disease * Evidence of bleeding diathesis or coagulopathy * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study * Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment * History of abdominal fistula, or intra-abdominal abscess within 6 months prior to study enrollment * Serious, non-healing wound, ulcer, or bone fracture * Proteinuria at screening as demonstrated by either * Urine protein:creatinine (UPC) ratio no less than 1.0 at screening OR * Urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible). * Known hypersensitivity to any component of Avastin * Pregnant (positive pregnancy test) or lactating. No effective means of contraception (men and women) in subjects of child-bearing potential